Rheos Biosciences

Rheos Medicines was a private immunometabolism-focused biotech company based in Cambridge, Massachusetts that developed precision medicines for autoimmune and inflammatory diseases. The company used a proprietary platform, referred to as MetPM, to analyze immune-cell metabolic pathways and identify both drug targets and biomarker-defined patient subsets. Its lead disclosed program was RHX-317, a small-molecule MALT1 inhibitor initially positioned for chronic graft-versus-host disease and other autoimmune or inflammatory conditions. Rheos also entered into a worldwide immunometabolism discovery and licensing collaboration with Roche in 2019. Recent private-market databases indicate the company is now out of business or has ceased operations, with no evidence of a public listing or announced acquisition.